Instituto de Investigación e Innovación en Ciencias Biomédicas (INiBICA)
Research institute
Hospital General de Elda
Elda, EspañaPublications in collaboration with researchers from Hospital General de Elda (1)
2004
-
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study
Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81